Certificate of Analysis for NR-52153

Acinetobacter baumannii, Strain MRSN 1171

Catalog No. NR-52153

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 1171 was isolated in 2006 from a human respiratory sample in the United States as part of a global surveillance program. *A. baumannii*, strain MRSN 1171 was deposited as sensitive to amikacin, colistin, imipenem and meropenem, intermediately resistant to tobramycin and resistant to ampicillin/sulbactam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, levofloxacin, tetracycline and trimethoprim/sulfamethoxazole. NR-52153 was produced by inoculation of BEI Resources seed lot 70038541 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70048832 **Manufacturing Date: 01DEC2021**

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C[1] 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility BBL™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Motile
VITEK® MS (MALDI-TOF)	*A. baumannii*	*A. baumannii* (99.9%)
Antibiotic Susceptibility Profile[2,3]		
Amikacin	Sensitive	Sensitive (12 to 16 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (64 µg/mL)
Cefepime	Resistant	Resistant (48 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Sensitive	Sensitive (≤ 1 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 32 µg/mL)
Meropenem	Sensitive	Sensitive (≤ 1 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (> 4 µg/mL)
Tobramycin	Intermediate	Sensitive (2 to 3 µg/mL)[4]
Tetracycline	Resistant	Resistant (≥ 256 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to *A. baumannii*, strain MRSN 1171 (GenBank: VHHG01000066.1)	99.9% sequence identity to *A. baumannii*, strain MRSN 1171 (GenBank: VHHG01000066.1)
Purity		
7 days at 37°C in an aerobic atmosphere with 5% CO_2 on Tryptic Soy agar with 5% defibrinated sheep's blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

Certificate of Analysis for NR-52153

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

[1]Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus and A. pittii*, which do not grow at 44°C.
[2]Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)
[3]Antibiotic susceptibility was tested using a combination of VITEK® 2 GN82, Sensititre™ GNX2F AST and E-test strips.
[4]*A. baumannii*, strain MRSN 1171 was deposited as intermediate to tobramycin, but showed a MIC of 2 to 3 µg/mL (interpreted as sensitive) for tobramycin during QC testing. Testing was performed in duplicate.

Figure 1: Colony Morphology



/Sonia Bjorum Brower/
Sonia Bjorum Brower 28 OCT 2022
Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

Support Provided by NIAID

BEI Resources
www.beiresources.org
E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898